Belgium· BE-AMP-SAM515857-00
Suliqua 100 U/ml - 33 µg/ml
A insulin glargine and lixisenatide product containing lixisenatide, registered in Belgium by Sanofi-Aventis Groupe. The same ATC class is registered in 10 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Insulin glargine and lixisenatide is registered in 10 of 19 countries.
Countries holding a registration under ATC A10AE54 (insulin glargine and lixisenatide), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 6 of them publish a price we can compare per daily dose
Insulin glargine and lixisenatide · ATC A10AE54
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Lixisenatide
- Manufacturer
- Sanofi-Aventis Groupe
- Country
- Belgium (BE)
- ATC code
- A10AE54
- ATC class
- Insulin glargine and lixisenatide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb3582541
- be_apb7723679
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin glargine and lixisenatide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a9371b63-8647-4332-b2dd-2c9c71a47e73 GET /v1/drugs/a9371b63-8647-4332-b2dd-2c9c71a47e73?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled pen",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Suliqua 100 U/ml - 33 µg/ml",
"name_fr": "Suliqua 100 U/ml - 33 µg/ml",
"name_nl": "Suliqua 100 U/ml - 33 µg/ml",
"amp_code": "SAM515857-00",
"strengths": [
"33.0000",
"100.0000",
"100.0000",
"33.0000"
],
"pack_count": 3,
"substances": [
"Lixisenatide",
"Insulin Glargine",
"Glycerol 85%",
"Sodium Hydroxide"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Insulin Glargine and Lixisenatide",
"authorisation_numbers": [
"EU/1/16/1157/004",
"EU/1/16/1157/003",
"EU/1/16/1157/006"
]
}See everything about insulin glargine and lixisenatide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.